The LAMP-CRISPR-Cas13a technique for detecting the CBASS mechanism of phage resistance in bacteria

Fecha de publicación:

Autores de IDIVAL

  • Daniel Pablo Marcos

    Autor

  • Jorge Calvo Montes

    Autor

Autores ajenos al IDIVAL

  • Ortiz-Cartagena, C
  • Fernández-Grela, P
  • Armán, L
  • Blasco, L
  • Bleriot, I
  • Fernández-García, L
  • Ibarguren-Quiles, C
  • Fernández-Cuenca, F
  • Barrio-Pujante, A
  • Aracil, B
  • Tomás, M

Unidades

Abstract

Introduction Antimicrobial resistance (AMR) is a major public health threat, driving the need for alternative treatments such as phage therapy. However, bacterial defense mechanisms, often regulated by the quorum sensing (QS) network and encoded in genomic islands (GIs), can generate phage-resistant mutants. Understanding these resistance mechanisms is essential for optimizing phage therapy. Methods This study analyzed 48 Klebsiella pneumoniae strains to identify pathogenicity islands (PAIs) containing anti-phage defense (APD) proteins. We constructed a knockout strain lacking the cyclase gene from the type II CBASS defense systems present in PAIs to investigate QS regulation and its role in cell viability. The LAMP-CRISPR-Cas13a technique was used to confirm gene knockout and to detect the main cyclase in type I CBASS systems, i.e., APECO1. Results A total of 309 pathogenicity islands (PAIs), containing 22.1% of anti-phage defense (APD) proteins, were identified. Type I and II CBASS APD systems were also detected in the genome of the 48, K. pneumoniae strains, and only two type II CBASS systems were located in PAIs. Alluding to these defense mechanisms, the QS revealed to be involved in the regulation of the type II CBASS systems contained in PAIs. Finally, the LAMP-CRISPR-Cas13a technology successfully detected the main cyclases habored in type I and II CBASS systems, respectively. Discussion The study findings highlight the regulatory role of the QS network in APD systems. Notably, this is the first study to develop an innovative biotechnological application for the LAMP-CRISPR-Cas13a rapid-technique (<2 h), thereby helping to optimize phage therapy by detecting bacterial resistance mechanisms and predicting the potential inefficacy of therapeutic phages and thus improving patient prognosis.

Datos de la publicación

ISSN/ISSNe:
1664-302X, 1664-302X

Frontiers in Microbiology  FRONTIERS MEDIA SA

Tipo:
Article
Páginas:
1550534-1550534
PubMed:
40196034

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • phage resistance; CBASS systems; CRISPR; Cas13a; Purification-free

Campos de Estudio

Proyectos asociados

CB21/13/00068 Fariñas Álvarez, María Del Carmen

Investigador Principal: María del Carmen Fariñas Álvarez

CB21/13/00068 . INSTITUTO DE SALUD CARLOS III. . 2022

Cita

Compartir